Telomir Pharmaceuticals, Inc.
TELO evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $80.5M
- Lead Asset:
- telomir-1 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for TELO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TELO
Telomir Pharmaceuticals, Inc. (TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, with a lead candidate Telomir-Zn (Telomir-1) advancing toward a Phase 1/2 trial in triple-negative breast cancer.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$80.5M
Cash Runway
—
Lead Asset
telomir-1 (Phase 1/Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Telomir Pharmaceuticals, Inc..
Similar companies
Telomir Pharmaceuticals, Inc. (TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, with a lead candidate Telomir-Zn (Telomir-1) advancing toward a Phase 1/2 trial in triple-negative breast cancer.
- Telomir is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease [news · published 2026-03-31].
- The company's lead candidate, Telomir-Zn (Telomir-1), is a first-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways [news · published 2026-03-31].
- FDA cleared the IND for Telomir-Zn in triple-negative breast cancer in April 2026, and the company plans to initiate a first-in-human Phase 1/2 trial in 1H 2026 [news · published 2026-04-30].
- As of 2026-06-30, the company reported a net loss of -$1.7M and shareholders' equity of $5.0M [sec].
- In October 2025, Telomir announced an agreement to acquire TELI Pharma to unify global rights to Telomir-1 [news · published 2025-10-21].
What works
- Telomir has achieved FDA clearance of its IND for Telomir-Zn in triple-negative breast cancer, a key regulatory milestone enabling clinical development [news · published 2026-04-30].
- The company's lead candidate is described as a first-in-class metal-modulating epigenetic therapy with preclinical efficacy and a favorable GLP safety profile [news · published 2026-03-31].
- Telomir has secured a partnership with a leading U.S. academic medical center to anchor its first-in-human trial [news · published 2026-04-30].
What to weigh
- Telomir is a clinical-stage company with no approved products and has reported a net loss of -$1.7M as of 2026-06-30, indicating it is not yet generating revenue from product sales [sec].
- The company's forward-looking statements are subject to significant risks and uncertainties, including those related to preclinical and clinical development, trial timing, and commercialization [sec · filed 2026-09-17].
- Shareholders' equity is relatively modest at $5.0M as of 2026-06-30, which may limit the company's financial runway for ongoing and future clinical trials [sec].
From the filings
Quoted directly from source documents.
FDA cleared the IND for Telomir-Zn in triple-negative breast cancer in April 2026.
“Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer”
News · April 30, 2026
Telomir announced an agreement to acquire TELI Pharma to unify global rights to Telomir-1.
“Telomir Pharmaceuticals To Acquire TELI Pharma, Unifying Global Rights To Telomir-1 Cancer And Aging Therapy”
News · October 21, 2025
Catalyst timeline
- 2026-10-01 · Phase2_Start: A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of Zn-Telomir Administered Orally as Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) — This is the planned start date for the first-in-human Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer.
Risks & what to watch (3)›
Key risks
- No approved products — Telomir has no approved products and relies on successful clinical development and regulatory approval for future revenue [sec · filed 2026-09-17].
- Financial constraints — With shareholders' equity of $5.0M as of 2026-06-30, the company may have limited financial resources to fund ongoing operations and trials [sec].
- Clinical trial uncertainties — The company's forward-looking statements are subject to risks related to preclinical and clinical development, trial timing, and results [sec · filed 2026-09-17].
What to watch
- Initiation and progress of the Phase 1/2 first-in-human trial for Telomir-Zn in triple-negative breast cancer, expected to start in 1H 2026 [news · published 2026-04-30].
- Completion of the acquisition of TELI Pharma to unify global rights to Telomir-1 [news · published 2025-10-21].
- Updates on the company's financial position and cash runway, given the modest shareholders' equity of $5.0M as of 2026-06-30 [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Telomir Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Telomir Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.07 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 21, 2026- % of float
- 5.9%
- Days to cover
- 15.1
- Shares short
- 1,225,205
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TELO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. (TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, with a lead candidate Telomir-Zn (Telomir-1) advancing toward a Phase 1/2 trial in triple-negative breast cancer.
What is Telomir Pharmaceuticals, Inc.'s lead drug candidate?
Telomir Pharmaceuticals, Inc.'s most advanced tracked candidate is telomir-1 (Phase 1/Phase 2) for Triple-Negative Breast Cancer (TNBC).
Who is the CEO of Telomir Pharmaceuticals, Inc.?
Mr. Erez Aminov is the chief executive officer of Telomir Pharmaceuticals, Inc. (TELO).
Where is Telomir Pharmaceuticals, Inc. headquartered?
Telomir Pharmaceuticals, Inc. (TELO) is headquartered in Miami, FL, United States.
What therapeutic areas does Telomir Pharmaceuticals, Inc. focus on?
Telomir Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.